Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and JULIE MAK

UroGen Pharma Stock Earns 91 RS Rating

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday.

IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research reveals that the best-performing stocks often have an 80 or higher RS Rating as they begin their largest runs.

Here Are 3 Keys For Successful Stock Investing

Is UroGen Pharma Stock A Buy?

UroGen Pharma stock is currently trading in a consolidation. While it's not currently an ideal time to invest, see if the biotech stock is able to offer and clear an appropriate buy point.

The biotech company reported 0% earnings growth in its most recent report, while sales growth came in at 9%.

UroGen Pharma stock earns the No. 112 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group.

 

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.